非急性期症状性前循环远端中型动脉病变的血管内治疗
本研究为单中心回顾性病例系列,纳入28例(29处病变)非急性期症状性前循环远端中型动脉疾病患者行血管内治疗,治疗成功率96.6%,围手术期无新发脑梗死或脑出血,随访再狭窄率43.5%,药物涂层球囊组再狭窄例数较少。
要点
- 血管内治疗非急性期症状性前循环远端中型动脉病变技术成功率高、围手术期并发症少。
- 术后再狭窄率较高(43.5%),需影像学随访监测。
- 药物涂层球囊组再狭窄例数少于普通球囊组和支架组,可能降低再狭窄。
核心结论
- 非急性期症状性aDMAD患者接受血管内治疗手术效果良好,但术后再狭窄率较高。
- 药物涂层球囊可能降低术后再狭窄的发生。
研究设计与样本
- 回顾性病例系列研究,纳入2018年5月至2024年3月北京医院神经外科收治的28例(29处病变)非急性期症状性aDMAD患者。
- 男性15例、女性13例,年龄(63.4±10.2)岁(范围36~82岁),症状出现时间均超过72 h。
- 病变位于大脑中动脉21处(72.4%)、大脑前动脉8处(27.6%),术前狭窄程度M(IQR)为90%(23%)(范围70%~100%)。
主要发现
- 治疗成功率为96.6%(28/29),症状出现至手术间隔60(66)d(范围9~210 d)。
- 单纯普通球囊扩张12例(13处)、药物涂层球囊扩张7例(7处)、支架置入9例(9处),术后残余狭窄程度20%(39%)(范围0~50%)。
- 围手术期无新发脑梗死、脑出血等并发症。
- 23处病变完成随访,随访时间12(15)个月(范围3~34个月),再狭窄10处(43.5%)、症状性再狭窄3处(13.0%)、再治疗4处(17.4%),随访中无新发脑出血及死亡。
- 再狭窄:普通球囊组6/10、药物涂层球囊组1/6、支架组3/7;症状性再狭窄:普通球囊组1/10、药物涂层球囊组0/6、支架组2/7。
临床怎么用
- 对规范化药物治疗后仍有责任血管相关区域短暂性脑缺血发作或脑梗死的非急性期症状性aDMAD患者,可考虑血管内治疗。
- 术后需影像学随访监测再狭窄,药物涂层球囊可能作为减少再狭窄的选择之一。
局限性
- 本研究为单中心回顾性病例系列,样本量小(28例29处病变),随访病变数有限(23处)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To examine the clinical effect of endovascular treatment for patients with non-acute symptomatic anterior circulation distal medium artery disease (aDMAD). Methods: This is a retrospective case series study.Retrospective analysis was conducted on the clinical data of 28 patients(29 lesions) with non-acute symptomatic aDMAD who underwent endovascular treatment at the Department of Neurosurgery,Beijing Hospital from May 2018 to March 2024. There were 15 males and 13 females,with an age of (63.4±10.2) years (range:36 to 82 years). The course of disease were more than 72 hours of all the patients. Confirmed by digital subtraction angiography,the lesion was located in distal anterior circulation and (or) medium arteries. Among them, 21 lesions (72.4%) located at middle cerebral artery and 8 lesions (27.6%) located at anterior cerebral artery.The median degree of stenosis before surgery (M(IQR)) was 90%(23%) (range:70% to 100%).After standardized drug treatment,there was still a transient ischemic attack or cerebral infarction in the vascular related area.The therapeutic effects and complications were analyzed,and the differences in the occurrence of target vessel restenosis under different interventional treatment methods were collected. Results: A total of 28 patients with 29 lesions underwent endovascular treatment, with a treatment success rate of 96.6% (28/29). The course of disease was 60(66)days (range:9 to 210 days). Simple plain balloon angioplasty was performed in 12 cases (13 lesions), drug-coated balloon (DCB) angioplasty in 7 cases (7 lesions), and stent placement in 9 cases (9 lesions). The median degree of stenosis after surgery was 20%(39%) (range:0 to 50%). There was no new cerebral infarctions,cerebral hemorrhages,or other complications during the perioperative period.Imaging follow-up was conducted on 23 lesions for 12(15)months(range:3 to 34 months),with 10 cases (43.5%) of restenosis,3 cases (13.0%) of symptomatic restenosis,and 4 cases (17.4%) of re-treatment. There were no new cases of cerebral hemorrhage or death during the follow-up process.The restenosis rate was 6/10 for the conventional balloon group,1/6 for the DCB group, and 3/7 for the stent group; the rate of symptomatic restenosis was 1/10 for the conventional balloon group,0/6 for the DCB group, and 2/7 for the stent group. Conclusions: Endovascular treatment for non-acute symptomatic aDMAD is relatively effective,but there is a high rate of restenosis postoperatively. DCB may reduce the occurrence of postoperative restenosis. 目的: 探讨非急性期症状性颅内前循环远端中型动脉粥样硬化性疾病(aDMAD)患者接受血管内治疗的临床效果。 方法: 本研究为回顾性病例系列研究。回顾性分析2018年5月至2024年3月北京医院神经外科收治的行血管内治疗的28例非急性期症状性aDMAD患者(29处病变)的临床资料。男性15例,女性13例,年龄(63.4±10.2)岁(范围:36~82岁)。患者出现症状时间均超过72 h,经数字减影血管造影证实,病变位于前循环远端和(或)中型动脉,其中病变位于大脑中动脉21处(72.4%),大脑前动脉8处(27.6%);狭窄程度[M(IQR)]为90%(23%)(范围:70%~100%)。经规范化药物治疗后,仍有责任血管相关区域的短暂性脑缺血发作或脑梗死发生。记录患者行血管内治疗的效果及并发症情况,分析不同介入治疗方式下目标血管再狭窄的发生情况。 结果: 28例患者(29处病变)均完成血管内治疗,症状出现至手术间隔60(66)d(范围:9~210 d),治疗成功率为96.6%(28/29)。其中单纯普通球囊扩张12例(13处),单纯药物涂层球囊扩张7例(7处),支架置入9例(9处)。术后残余狭窄程度为20%(39%)(范围:0~50%)。围手术期无新发脑梗死、脑出血等并发症。23例患者(23处病变)完成随访,随访时间为12(15)个月(范围:3~34个月)。23处病变中,再狭窄10处(43.5%),症状性再狭窄3处(13.0%),再治疗4处(17.4%)。随访过程中无新发脑出血及死亡。普通球囊组发生再狭窄6例(6/10),药物涂层球囊组1例(1/6),支架组3例(3/7);普通球囊组发生症状性再狭窄1例(1/10),支架组2例(2/7),药物涂层球囊组未发生。 结论: 非急性期aDMAD患者接受血管内治疗的手术效果良好,但术后有较高的再狭窄率,药物涂层球囊可能降低术后再狭窄的发生。.
引用
- Yang XM, Lu J, Qi P, et al. [Endovascular treatment of non-acute symptomatic anterior circulation distal medium artery disease]. Zhonghua Wai Ke Za Zhi. 2024. PMID: 39606992. doi:10.3760/cma.j.cn112139-20240902-00409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。